Edition:
United States

People: Akorn Inc (AKRX.O)

AKRX.O on Nasdaq

3.84USD
19 Jul 2019
Change (% chg)

$-0.03 (-0.78%)
Prev Close
$3.87
Open
$3.87
Day's High
$3.97
Day's Low
$3.77
Volume
858,997
Avg. Vol
2,404,119
52-wk High
$19.65
52-wk Low
$2.64

Boothe, Douglas 

Mr. Douglas S. Boothe is President, Chief Executive Officer, Director of the company. Prior to joining Akorn, Boothe most recently served as president of the generics division of publicly held Impax Laboratories, which developed, manufactured and marketed bioequivalent pharmaceuticals and was acquired by Amneal Pharmaceuticals LLC. Prior to Impax Laboratories, Mr. Boothe was the executive vice president and general manager of Perrigo Company Plc, with responsibility for the U.S. pharmaceuticals business, which included generics and specialty pharmaceutical products. He also served as the CEO of Actavis Inc., the U.S. manufacturing and marketing division of Actavis Group, and held senior positions at Alpharma and Pharmacia Corp. Following Mr. Boothe’s time at Impax Laboratories, he served as principal consultant for his own consulting company, Channel Advantage Consulting LLC. Mr. Boothe received his undergraduate degree from Princeton University and his MBA from the Wharton School of Business at the University of Pennsylvania.

Basic Compensation

Total Annual Compensation, --
Restricted Stock Awards, --
Long-Term Incentive Plans, --
All Other, --
Fiscal Year Total, --

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --